A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis
Public ClinicalTrials.gov record NCT05314517. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-Controlled Phase 2 Study With Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects With Chronic Pulmonary Sarcoidosis
Study identification
- NCT ID
- NCT05314517
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Kinevant Sciences GmbH
- Industry
- Enrollment
- 107 participants
Conditions and interventions
Conditions
Interventions
- Namilumab Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 30, 2022
- Primary completion
- Oct 15, 2024
- Completion
- Apr 8, 2025
- Last update posted
- Sep 11, 2025
2022 – 2025
United States locations
- U.S. sites
- 24
- U.S. states
- 17
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Kinevant Study Site | Birmingham | Alabama | 35233 | — |
| Kinevant Study Site | Palo Alto | California | 94304 | — |
| Kinevant Study Site | Valencia | California | 91355 | — |
| Kinevant Study Site | Denver | Colorado | 80206 | — |
| Kinevant Study Site | Gainesville | Florida | 32610 | — |
| Kinevant Study Site | Augusta | Georgia | 29841 | — |
| Kinevant Study Site | Chicago | Illinois | 60612 | — |
| Kinevant Study Site | Iowa City | Iowa | 52242 | — |
| Kinevant Study Site | Kansas City | Kansas | 66160 | — |
| Kinevant Study Site | New Orleans | Louisiana | 70115 | — |
| Kinevant Study Site | Baltimore | Maryland | 21234 | — |
| Kinevant Study Site | Minneapolis | Minnesota | 55414 | — |
| Kinevant Study Site | Rochester | Minnesota | 55905 | — |
| Kinevant Study Site | Greenville | North Carolina | 27834 | — |
| Kinevant Study Site | Cincinnati | Ohio | 45219 | — |
| Kinevant Study Site | Cleveland | Ohio | 44195 | — |
| Kinevant Study Site | Philadelphia | Pennsylvania | 19140 | — |
| Kinevant Study Site | Pittsburgh | Pennsylvania | 15213 | — |
| Kinevant Study Site | Charleston | South Carolina | 29425 | — |
| Kinevant Study Site | Rock Hill | South Carolina | 29732 | — |
| Kinevant Study Site | Dallas | Texas | 75390 | — |
| Kinevant Study Site | Houston | Texas | 77030 | — |
| Kinevant Study Site | Charlottesville | Virginia | 22908 | — |
| Kinevant Study Site | Falls Church | Virginia | 22042 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05314517, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 11, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05314517 live on ClinicalTrials.gov.